Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GSK3B | P49841 | 3/20 | 0.53 |
| ▸ | CRHBP | P24387 | 1/20 | 0.52 |
| ▸ | CRHR2 | Q13324 | 1/20 | 0.52 |
| ▸ | NAT1 | P18440 | 3/20 | 0.48 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.47 |
| ▸ | IDH1 | O75874 | 1/20 | 0.46 |
| ▸ | CISD1 | Q9NZ45 | 2/20 | 0.44 |
| ▸ | GAA | P10253 | 2/20 | 0.44 |
| ▸ | MGAM | O43451 | 1/20 | 0.44 |
| ▸ | SI | P14410 | 1/20 | 0.44 |
| ▸ | MGAM2 | Q2M2H8 | 1/20 | 0.44 |
| ▸ | ADAMTS5 | Q9UNA0 | 1/20 | 0.43 |
| ▸ | PIM1 | P11309 | 1/20 | 0.43 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.43 |
| ▸ | PIM3 | Q86V86 | 1/20 | 0.43 |
| ▸ | DYRK2 | Q92630 | 1/20 | 0.43 |
| ▸ | PIM2 | Q9P1W9 | 1/20 | 0.43 |
| ▸ | MYC | P01106 | 1/20 | 0.42 |
| ▸ | MAX | P61244 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6704819 | 1.00 | GSK3B (0.53) | GSK3BCRHBPCRHR2NAT1PTGS2 | |
| SCHEMBL6618412 | 0.79 | ERN1 (0.47) | CRHBPCRHR2 | |
| SCHEMBL6451356 | 0.77 | GSK3B (0.49) | GSK3BNAT1PTGS2GAAMGAM | |
| SCHEMBL6451359 | 0.77 | GSK3B (0.49) | GSK3BNAT1PTGS2GAAMGAM | |
| SCHEMBL6704722 | 0.74 | CA2 (0.43) | CRHBPCRHR2CISD1ALDH1A1 | |
| SCHEMBL18103005 | 0.72 | NAT1 (0.85) | CRHBPCRHR2NAT1CISD1ADAMTS5 | |
| SCHEMBL18103002 | 0.71 | NAT1 (0.74) | CRHBPCRHR2NAT1CISD1ADAMTS5 | |
| SCHEMBL18102890 | 0.71 | NAT1 (0.76) | GSK3BCRHBPCRHR2NAT1CISD1 | |
| SCHEMBL19991267 | 0.71 | NAT1 (0.76) | GSK3BCRHBPCRHR2NAT1CISD1 | |
| SCHEMBL18102962 | 0.71 | NAT1 (0.76) | GSK3BCRHBPCRHR2NAT1CISD1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040097566-A1 | 2-Substituted thiazolidinone and oxazolidinone derivatives for the inhibition of phosphatases and the treatment of cancer | INCYTE SAN DIEGO INCORPORATED | 2004-05-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040097566-A1 | 2-Substituted thiazolidinone and oxazolidinone derivatives for the inhibition of phosphatases and the treatment of cancer | PTPA, PTPRC, PTPRCAP | GSK3B 148/4885CRHBP 3440/4885CRHR2 3000/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.